GRN and early-onset autosomal dominant Alzheimer disease: Primary endpoints are safety and progranulin levels; secondary endpoints are Clinical Dementia Rating (CDR) plus National Alzheimer’s Disease Coordinating Center (NACC) Frontotemporal Lobar Degeneration (FTLD) rating scale and levels of neurofilament light chain (NfL), and multiple exploratory endpoints include BMP levels.